Global Live Attenuated Vaccines Market Growth 2025-2031

October 2025 | 90 pages | ID: G59FCFE695E1EN
LP Information

Abstracts

The global Live Attenuated Vaccines market size is predicted to grow from US$ 30820 million in 2025 to US$ 44540 million in 2031; it is expected to grow at a CAGR of 6.3% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or 'live'). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by 'killing' the virus (inactivated vaccine).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Live Attenuated Vaccines Industry Forecast? looks at past sales and reviews total world Live Attenuated Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected Live Attenuated Vaccines sales for 2025 through 2031. With Live Attenuated Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Live Attenuated Vaccines industry.

This Insight Report provides a comprehensive analysis of the global Live Attenuated Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Live Attenuated Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Live Attenuated Vaccines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Live Attenuated Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Live Attenuated Vaccines.

This report presents a comprehensive overview, market shares, and growth opportunities of Live Attenuated Vaccines market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Bacterial
• Viral

Segmentation by Application:

• Hospitals
• Clinics
• Research Institutes
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• GlaxoSmithKline
• Merck
• Pfizer
• Astellas Pharma
• Johnson & Johnson
• CSL
• Sanofi
• Serum Institute Of India

Key Questions Addressed in this Report

What is the 10-year outlook for the global Live Attenuated Vaccines market?
What factors are driving Live Attenuated Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Live Attenuated Vaccines market opportunities vary by end market size?
How does Live Attenuated Vaccines break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Live Attenuated Vaccines Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Live Attenuated Vaccines by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Live Attenuated Vaccines by Country/Region, 2020, 2024 & 2031
2.2 Live Attenuated Vaccines Segment by Type
  2.2.1 Bacterial
  2.2.2 Viral
2.3 Live Attenuated Vaccines Sales by Type
  2.3.1 Global Live Attenuated Vaccines Sales Market Share by Type (2020-2025)
  2.3.2 Global Live Attenuated Vaccines Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Live Attenuated Vaccines Sale Price by Type (2020-2025)
2.4 Live Attenuated Vaccines Segment by Application
  2.4.1 Hospitals
  2.4.2 Clinics
  2.4.3 Research Institutes
  2.4.4 Others
2.5 Live Attenuated Vaccines Sales by Application
  2.5.1 Global Live Attenuated Vaccines Sale Market Share by Application (2020-2025)
  2.5.2 Global Live Attenuated Vaccines Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Live Attenuated Vaccines Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Live Attenuated Vaccines Breakdown Data by Company
  3.1.1 Global Live Attenuated Vaccines Annual Sales by Company (2020-2025)
  3.1.2 Global Live Attenuated Vaccines Sales Market Share by Company (2020-2025)
3.2 Global Live Attenuated Vaccines Annual Revenue by Company (2020-2025)
  3.2.1 Global Live Attenuated Vaccines Revenue by Company (2020-2025)
  3.2.2 Global Live Attenuated Vaccines Revenue Market Share by Company (2020-2025)
3.3 Global Live Attenuated Vaccines Sale Price by Company
3.4 Key Manufacturers Live Attenuated Vaccines Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Live Attenuated Vaccines Product Location Distribution
  3.4.2 Players Live Attenuated Vaccines Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LIVE ATTENUATED VACCINES BY GEOGRAPHIC REGION

4.1 World Historic Live Attenuated Vaccines Market Size by Geographic Region (2020-2025)
  4.1.1 Global Live Attenuated Vaccines Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Live Attenuated Vaccines Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Live Attenuated Vaccines Market Size by Country/Region (2020-2025)
  4.2.1 Global Live Attenuated Vaccines Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Live Attenuated Vaccines Annual Revenue by Country/Region (2020-2025)
4.3 Americas Live Attenuated Vaccines Sales Growth
4.4 APAC Live Attenuated Vaccines Sales Growth
4.5 Europe Live Attenuated Vaccines Sales Growth
4.6 Middle East & Africa Live Attenuated Vaccines Sales Growth

5 AMERICAS

5.1 Americas Live Attenuated Vaccines Sales by Country
  5.1.1 Americas Live Attenuated Vaccines Sales by Country (2020-2025)
  5.1.2 Americas Live Attenuated Vaccines Revenue by Country (2020-2025)
5.2 Americas Live Attenuated Vaccines Sales by Type (2020-2025)
5.3 Americas Live Attenuated Vaccines Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Live Attenuated Vaccines Sales by Region
  6.1.1 APAC Live Attenuated Vaccines Sales by Region (2020-2025)
  6.1.2 APAC Live Attenuated Vaccines Revenue by Region (2020-2025)
6.2 APAC Live Attenuated Vaccines Sales by Type (2020-2025)
6.3 APAC Live Attenuated Vaccines Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Live Attenuated Vaccines by Country
  7.1.1 Europe Live Attenuated Vaccines Sales by Country (2020-2025)
  7.1.2 Europe Live Attenuated Vaccines Revenue by Country (2020-2025)
7.2 Europe Live Attenuated Vaccines Sales by Type (2020-2025)
7.3 Europe Live Attenuated Vaccines Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Live Attenuated Vaccines by Country
  8.1.1 Middle East & Africa Live Attenuated Vaccines Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Live Attenuated Vaccines Revenue by Country (2020-2025)
8.2 Middle East & Africa Live Attenuated Vaccines Sales by Type (2020-2025)
8.3 Middle East & Africa Live Attenuated Vaccines Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Live Attenuated Vaccines
10.3 Manufacturing Process Analysis of Live Attenuated Vaccines
10.4 Industry Chain Structure of Live Attenuated Vaccines

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Live Attenuated Vaccines Distributors
11.3 Live Attenuated Vaccines Customer

12 WORLD FORECAST REVIEW FOR LIVE ATTENUATED VACCINES BY GEOGRAPHIC REGION

12.1 Global Live Attenuated Vaccines Market Size Forecast by Region
  12.1.1 Global Live Attenuated Vaccines Forecast by Region (2026-2031)
  12.1.2 Global Live Attenuated Vaccines Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Live Attenuated Vaccines Forecast by Type (2026-2031)
12.7 Global Live Attenuated Vaccines Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 GlaxoSmithKline
  13.1.1 GlaxoSmithKline Company Information
  13.1.2 GlaxoSmithKline Live Attenuated Vaccines Product Portfolios and Specifications
  13.1.3 GlaxoSmithKline Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 GlaxoSmithKline Main Business Overview
  13.1.5 GlaxoSmithKline Latest Developments
13.2 Merck
  13.2.1 Merck Company Information
  13.2.2 Merck Live Attenuated Vaccines Product Portfolios and Specifications
  13.2.3 Merck Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Merck Main Business Overview
  13.2.5 Merck Latest Developments
13.3 Pfizer
  13.3.1 Pfizer Company Information
  13.3.2 Pfizer Live Attenuated Vaccines Product Portfolios and Specifications
  13.3.3 Pfizer Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Pfizer Main Business Overview
  13.3.5 Pfizer Latest Developments
13.4 Astellas Pharma
  13.4.1 Astellas Pharma Company Information
  13.4.2 Astellas Pharma Live Attenuated Vaccines Product Portfolios and Specifications
  13.4.3 Astellas Pharma Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Astellas Pharma Main Business Overview
  13.4.5 Astellas Pharma Latest Developments
13.5 Johnson & Johnson
  13.5.1 Johnson & Johnson Company Information
  13.5.2 Johnson & Johnson Live Attenuated Vaccines Product Portfolios and Specifications
  13.5.3 Johnson & Johnson Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Johnson & Johnson Main Business Overview
  13.5.5 Johnson & Johnson Latest Developments
13.6 CSL
  13.6.1 CSL Company Information
  13.6.2 CSL Live Attenuated Vaccines Product Portfolios and Specifications
  13.6.3 CSL Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 CSL Main Business Overview
  13.6.5 CSL Latest Developments
13.7 Sanofi
  13.7.1 Sanofi Company Information
  13.7.2 Sanofi Live Attenuated Vaccines Product Portfolios and Specifications
  13.7.3 Sanofi Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Sanofi Main Business Overview
  13.7.5 Sanofi Latest Developments
13.8 Serum Institute Of India
  13.8.1 Serum Institute Of India Company Information
  13.8.2 Serum Institute Of India Live Attenuated Vaccines Product Portfolios and Specifications
  13.8.3 Serum Institute Of India Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Serum Institute Of India Main Business Overview
  13.8.5 Serum Institute Of India Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Live Attenuated Vaccines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Live Attenuated Vaccines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Bacterial
Table 4. Major Players of Viral
Table 5. Global Live Attenuated Vaccines Sales by Type (2020-2025) & (K Units)
Table 6. Global Live Attenuated Vaccines Sales Market Share by Type (2020-2025)
Table 7. Global Live Attenuated Vaccines Revenue by Type (2020-2025) & ($ million)
Table 8. Global Live Attenuated Vaccines Revenue Market Share by Type (2020-2025)
Table 9. Global Live Attenuated Vaccines Sale Price by Type (2020-2025) & (USD/Unit)
Table 10. Global Live Attenuated Vaccines Sale by Application (2020-2025) & (K Units)
Table 11. Global Live Attenuated Vaccines Sale Market Share by Application (2020-2025)
Table 12. Global Live Attenuated Vaccines Revenue by Application (2020-2025) & ($ million)
Table 13. Global Live Attenuated Vaccines Revenue Market Share by Application (2020-2025)
Table 14. Global Live Attenuated Vaccines Sale Price by Application (2020-2025) & (USD/Unit)
Table 15. Global Live Attenuated Vaccines Sales by Company (2020-2025) & (K Units)
Table 16. Global Live Attenuated Vaccines Sales Market Share by Company (2020-2025)
Table 17. Global Live Attenuated Vaccines Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Live Attenuated Vaccines Revenue Market Share by Company (2020-2025)
Table 19. Global Live Attenuated Vaccines Sale Price by Company (2020-2025) & (USD/Unit)
Table 20. Key Manufacturers Live Attenuated Vaccines Producing Area Distribution and Sales Area
Table 21. Players Live Attenuated Vaccines Products Offered
Table 22. Live Attenuated Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Live Attenuated Vaccines Sales by Geographic Region (2020-2025) & (K Units)
Table 26. Global Live Attenuated Vaccines Sales Market Share Geographic Region (2020-2025)
Table 27. Global Live Attenuated Vaccines Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Live Attenuated Vaccines Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Live Attenuated Vaccines Sales by Country/Region (2020-2025) & (K Units)
Table 30. Global Live Attenuated Vaccines Sales Market Share by Country/Region (2020-2025)
Table 31. Global Live Attenuated Vaccines Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Live Attenuated Vaccines Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Live Attenuated Vaccines Sales by Country (2020-2025) & (K Units)
Table 34. Americas Live Attenuated Vaccines Sales Market Share by Country (2020-2025)
Table 35. Americas Live Attenuated Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Live Attenuated Vaccines Sales by Type (2020-2025) & (K Units)
Table 37. Americas Live Attenuated Vaccines Sales by Application (2020-2025) & (K Units)
Table 38. APAC Live Attenuated Vaccines Sales by Region (2020-2025) & (K Units)
Table 39. APAC Live Attenuated Vaccines Sales Market Share by Region (2020-2025)
Table 40. APAC Live Attenuated Vaccines Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Live Attenuated Vaccines Sales by Type (2020-2025) & (K Units)
Table 42. APAC Live Attenuated Vaccines Sales by Application (2020-2025) & (K Units)
Table 43. Europe Live Attenuated Vaccines Sales by Country (2020-2025) & (K Units)
Table 44. Europe Live Attenuated Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Live Attenuated Vaccines Sales by Type (2020-2025) & (K Units)
Table 46. Europe Live Attenuated Vaccines Sales by Application (2020-2025) & (K Units)
Table 47. Middle East & Africa Live Attenuated Vaccines Sales by Country (2020-2025) & (K Units)
Table 48. Middle East & Africa Live Attenuated Vaccines Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Live Attenuated Vaccines Sales by Type (2020-2025) & (K Units)
Table 50. Middle East & Africa Live Attenuated Vaccines Sales by Application (2020-2025) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Live Attenuated Vaccines
Table 52. Key Market Challenges & Risks of Live Attenuated Vaccines
Table 53. Key Industry Trends of Live Attenuated Vaccines
Table 54. Live Attenuated Vaccines Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Live Attenuated Vaccines Distributors List
Table 57. Live Attenuated Vaccines Customer List
Table 58. Global Live Attenuated Vaccines Sales Forecast by Region (2026-2031) & (K Units)
Table 59. Global Live Attenuated Vaccines Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Live Attenuated Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 61. Americas Live Attenuated Vaccines Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Live Attenuated Vaccines Sales Forecast by Region (2026-2031) & (K Units)
Table 63. APAC Live Attenuated Vaccines Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Live Attenuated Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 65. Europe Live Attenuated Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Live Attenuated Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Middle East & Africa Live Attenuated Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Live Attenuated Vaccines Sales Forecast by Type (2026-2031) & (K Units)
Table 69. Global Live Attenuated Vaccines Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Live Attenuated Vaccines Sales Forecast by Application (2026-2031) & (K Units)
Table 71. Global Live Attenuated Vaccines Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. GlaxoSmithKline Basic Information, Live Attenuated Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 73. GlaxoSmithKline Live Attenuated Vaccines Product Portfolios and Specifications
Table 74. GlaxoSmithKline Live Attenuated Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 75. GlaxoSmithKline Main Business
Table 76. GlaxoSmithKline Latest Developments
Table 77. Merck Basic Information, Live Attenuated Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 78. Merck Live Attenuated Vaccines Product Portfolios and Specifications
Table 79. Merck Live Attenuated Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Merck Main Business
Table 81. Merck Latest Developments
Table 82. Pfizer Basic Information, Live Attenuated Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer Live Attenuated Vaccines Product Portfolios and Specifications
Table 84. Pfizer Live Attenuated Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. Astellas Pharma Basic Information, Live Attenuated Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 88. Astellas Pharma Live Attenuated Vaccines Product Portfolios and Specifications
Table 89. Astellas Pharma Live Attenuated Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 90. Astellas Pharma Main Business
Table 91. Astellas Pharma Latest Developments
Table 92. Johnson & Johnson Basic Information, Live Attenuated Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 93. Johnson & Johnson Live Attenuated Vaccines Product Portfolios and Specifications
Table 94. Johnson & Johnson Live Attenuated Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 95. Johnson & Johnson Main Business
Table 96. Johnson & Johnson Latest Developments
Table 97. CSL Basic Information, Live Attenuated Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 98. CSL Live Attenuated Vaccines Product Portfolios and Specifications
Table 99. CSL Live Attenuated Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 100. CSL Main Business
Table 101. CSL Latest Developments
Table 102. Sanofi Basic Information, Live Attenuated Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 103. Sanofi Live Attenuated Vaccines Product Portfolios and Specifications
Table 104. Sanofi Live Attenuated Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 105. Sanofi Main Business
Table 106. Sanofi Latest Developments
Table 107. Serum Institute Of India Basic Information, Live Attenuated Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 108. Serum Institute Of India Live Attenuated Vaccines Product Portfolios and Specifications
Table 109. Serum Institute Of India Live Attenuated Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 110. Serum Institute Of India Main Business
Table 111. Serum Institute Of India Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Live Attenuated Vaccines
Figure 2. Live Attenuated Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Live Attenuated Vaccines Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Live Attenuated Vaccines Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Live Attenuated Vaccines Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Live Attenuated Vaccines Sales Market Share by Country/Region (2024)
Figure 10. Live Attenuated Vaccines Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Bacterial
Figure 12. Product Picture of Viral
Figure 13. Global Live Attenuated Vaccines Sales Market Share by Type in 2025
Figure 14. Global Live Attenuated Vaccines Revenue Market Share by Type (2020-2025)
Figure 15. Live Attenuated Vaccines Consumed in Hospitals
Figure 16. Global Live Attenuated Vaccines Market: Hospitals (2020-2025) & (K Units)
Figure 17. Live Attenuated Vaccines Consumed in Clinics
Figure 18. Global Live Attenuated Vaccines Market: Clinics (2020-2025) & (K Units)
Figure 19. Live Attenuated Vaccines Consumed in Research Institutes
Figure 20. Global Live Attenuated Vaccines Market: Research Institutes (2020-2025) & (K Units)
Figure 21. Live Attenuated Vaccines Consumed in Others
Figure 22. Global Live Attenuated Vaccines Market: Others (2020-2025) & (K Units)
Figure 23. Global Live Attenuated Vaccines Sale Market Share by Application (2024)
Figure 24. Global Live Attenuated Vaccines Revenue Market Share by Application in 2025
Figure 25. Live Attenuated Vaccines Sales by Company in 2025 (K Units)
Figure 26. Global Live Attenuated Vaccines Sales Market Share by Company in 2025
Figure 27. Live Attenuated Vaccines Revenue by Company in 2025 ($ millions)
Figure 28. Global Live Attenuated Vaccines Revenue Market Share by Company in 2025
Figure 29. Global Live Attenuated Vaccines Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Live Attenuated Vaccines Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Live Attenuated Vaccines Sales 2020-2025 (K Units)
Figure 32. Americas Live Attenuated Vaccines Revenue 2020-2025 ($ millions)
Figure 33. APAC Live Attenuated Vaccines Sales 2020-2025 (K Units)
Figure 34. APAC Live Attenuated Vaccines Revenue 2020-2025 ($ millions)
Figure 35. Europe Live Attenuated Vaccines Sales 2020-2025 (K Units)
Figure 36. Europe Live Attenuated Vaccines Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Live Attenuated Vaccines Sales 2020-2025 (K Units)
Figure 38. Middle East & Africa Live Attenuated Vaccines Revenue 2020-2025 ($ millions)
Figure 39. Americas Live Attenuated Vaccines Sales Market Share by Country in 2025
Figure 40. Americas Live Attenuated Vaccines Revenue Market Share by Country (2020-2025)
Figure 41. Americas Live Attenuated Vaccines Sales Market Share by Type (2020-2025)
Figure 42. Americas Live Attenuated Vaccines Sales Market Share by Application (2020-2025)
Figure 43. United States Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Live Attenuated Vaccines Sales Market Share by Region in 2025
Figure 48. APAC Live Attenuated Vaccines Revenue Market Share by Region (2020-2025)
Figure 49. APAC Live Attenuated Vaccines Sales Market Share by Type (2020-2025)
Figure 50. APAC Live Attenuated Vaccines Sales Market Share by Application (2020-2025)
Figure 51. China Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 55. India Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 57. China Taiwan Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Live Attenuated Vaccines Sales Market Share by Country in 2025
Figure 59. Europe Live Attenuated Vaccines Revenue Market Share by Country (2020-2025)
Figure 60. Europe Live Attenuated Vaccines Sales Market Share by Type (2020-2025)
Figure 61. Europe Live Attenuated Vaccines Sales Market Share by Application (2020-2025)
Figure 62. Germany Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 63. France Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Live Attenuated Vaccines Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Live Attenuated Vaccines Sales Market Share by Type (2020-2025)
Figure 69. Middle East & Africa Live Attenuated Vaccines Sales Market Share by Application (2020-2025)
Figure 70. Egypt Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 73. Turkey Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Live Attenuated Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Live Attenuated Vaccines in 2025
Figure 76. Manufacturing Process Analysis of Live Attenuated Vaccines
Figure 77. Industry Chain Structure of Live Attenuated Vaccines
Figure 78. Channels of Distribution
Figure 79. Global Live Attenuated Vaccines Sales Market Forecast by Region (2026-2031)
Figure 80. Global Live Attenuated Vaccines Revenue Market Share Forecast by Region (2026-2031)
Figure 81. Global Live Attenuated Vaccines Sales Market Share Forecast by Type (2026-2031)
Figure 82. Global Live Attenuated Vaccines Revenue Market Share Forecast by Type (2026-2031)
Figure 83. Global Live Attenuated Vaccines Sales Market Share Forecast by Application (2026-2031)
Figure 84. Global Live Attenuated Vaccines Revenue Market Share Forecast by Application (2026-2031)